AbbVie’s upadacitinib is currently being analysed in Phase III trials for alopecia areata and giant cell arteritis among others. © AbbVie Inc. All rights reserved.

AbbVie has revealed positive data from a post-hoc analysis of the Phase III Measure Up 1 and Measure Up 2 clinical trials of RINVOQ (upadacitinib) in treating moderate-to-severe atopic dermatitis (AD).

The trials assessed 15mg or 30mg doses of upadacitinib compared to placebo to treat AD patients, particularly those with varying degrees of disease severity in the head and neck areas.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

These randomised, multicentre, double-blind, parallel-group, placebo-controlled studies assessed the efficacy and safety of RINVOQ in adults and adolescents aged 12 years or older who are systemic treatment candidates.

In the analysis, various treatment targets – such as attaining near complete skin clearance in the head and neck region (EASI Head & Neck score <1), near complete skin clearance (EASI 90), no to little itch (WP-NRS 0/1) and minimal or no impact on quality of life (DLQI 0/1) – were evaluated in patients treated with upadacitinib.

The post-hoc analysis findings indicated that a greater proportion of trial subjects treated with both doses of upadacitinib attained near-complete skin clearance in the head and neck region, reduced impact on quality of life, and minimal disease activity at week 16 versus placebo.

Minimal disease activity meant that the patients had near complete skin clearance (EASI 90) and no to little itch (WP-NRS 0/1).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

A selective and reversible JAK inhibitor, RINVOQ is under investigation for various immune-mediated inflammatory diseases.

Apart from AD, the asset is currently being analysed in Phase III trials for alopecia areata, giant cell arteritis, Takayasu arteritis, hidradenitis suppurativa, systemic lupus erythematosus, and vitiligo.

AbbVie immunology global medical affairs vice-president Andrew Anisfeld said: “Despite taking steps to manage their condition, many patients with atopic dermatitis continue to live with debilitating symptoms, especially in highly visible areas such as head and neck that can intensify one’s physical and emotional burden. 

“These data contribute to our ongoing commitment to elevate the standard of care in atopic dermatitis so patients can strive for the best possible outcomes.”

In June, the company reported positive data from the Phase II PICCOLO trial of mirvetuximab soravtansine (ELAHERE) monotherapy in heavily pre-treated high folate receptor-alpha (FRα)-positive platinum-sensitive ovarian cancer (PSOC) patients.